Oral care composition

Abstract

The present invention relates to oral care compositions comprising one or more of the following compounds or compositions: Iris root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract. Oral care products incorporating such compositions and related methods are also provided.

Description

[Technical Field]

[0001] Oral diseases such as dental caries are highly prevalent in society. They can cause chronic and acute pain to affected individuals and can be fatal. Oral hygiene plays an important role in reducing the impact of such diseases. Examples of oral hygiene include regular tooth brushing, flossing, tongue cleaners, and of course, routine visits to an oral health care practitioner.

[0002] For example, oral care preparations such as mouthwashes or mouthrinses have been known for a long time and have been developed to cleanse and refresh the oral cavity or oral surfaces by inhibiting or killing microorganisms that cause malodor, tooth decay, dental caries, gum disease, gingivitis, and periodontal disorders.

[0003] While oral care compositions with antimicrobial activity are known, there is a need in society for additional compositions to improve oral hygiene and reduce instances of oral disease.

[0004] Summary of the Invention The present invention provides a solution to the above problems by providing an oral care composition comprising one or more of the following compounds or compositions: Iris species root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract.

[0005] An embodiment of the present invention provides an oral care composition according to the invention, wherein the compound or composition is present in a concentration of 0.001 to 5%, particularly preferably 0.005 to 3%, preferably 0.05 to 2.5%, preferably 0.1 to 2.5%, preferably 0.5 to 2%, in each case relative to the total weight of the oral care composition according to the invention.

[0006] Certain embodiments of the present invention provide oral care compositions of the present invention further comprising one or more of the following ingredients: a flavor system, a coolant, a surfactant, a humectant, a pigment, an antimicrobial agent, a thickener, a fluoride source, an anti-tartar agent, and / or a preservative.

[0007] Some embodiments of the present invention provide oral care compositions of the present invention that are coated or encapsulated.

[0008] A further aspect of the present invention provides an oral care or consumer product, preferably a nutritional or pleasure product, comprising the oral care composition of the present invention.

[0009] In some embodiments of the present invention, the oral care product is selected from the group consisting of toothpaste, tooth powder, tooth gel, tooth cleaning liquid, tooth cleaning foam, tooth tablet, mouthwash, mouth rinse, mouth spray, dental floss, chewing gum, dental aligners, lozenges, denture effervescent tablets; denture effervescent tablets and dental aligners.

[0010] A further aspect of the present invention provides a method for treating or preventing erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis and / or dental caries, the method comprising the step of applying a composition according to the present invention to the oral cavity of a person in need thereof.

[0011] A further aspect of the present invention provides an oral care composition comprising one or more of the following compounds or compositions: Iris species root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract, for use in treating an oral condition.

[0012] According to certain embodiments of the present invention, the oral condition is selected from the group consisting of erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis, dental caries or a combination thereof.

[0013] A further aspect of the present invention provides the use of the oral care composition of the present invention to treat or prevent erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis and / or dental caries.

[0014] A further aspect of the present invention is a method for identifying a test composition having use in oral health care, comprising the steps of: (a) assaying whether the test composition reduces bacterial adhesion; and / or (b) assaying whether the test composition reduces biofilm formation; and / or (c) assaying whether the test composition disrupts the biofilm; and / or (d) assaying whether the test composition reduces the pathogenicity of Porphyromonas gingivalis. Including, Methods are provided in which compositions that test positive in one or more assays are useful in oral health care compositions.

[0015] In one embodiment of the method for identifying a test composition, the assay in step (a) comprises exposing a substrate to saliva and / or bacteria in the presence or absence of a test composition, and determining whether the test composition reduces bacterial adhesion to the substrate.

[0016] In one embodiment of the method for identifying a test composition, the assay in step (b) comprises exposing the substrate to saliva and / or bacteria under incubation conditions for at least 24 hours, then exposing the incubation mixture to the test composition, and determining whether the test composition reduces biofilm formation on the substrate.

[0017] In one embodiment of the method for identifying a test composition, the assay in step (c) comprises exposing the substrate to saliva and / or bacteria under incubation conditions for at least 72 hours to allow a biofilm to form on the substrate, then exposing the incubation mixture to the test composition and determining whether the test composition disrupts the biofilm.

[0018] In one embodiment of the method for identifying a test composition, the effect of the test composition on a biofilm is determined by harvesting the biofilm and determining the amount and type of bacteria present in the biofilm.

[0019] Certain embodiments of the method for identifying a test composition further include preparing an oral care composition using the test composition that is positive in one or more assays.

[0020] A further aspect of the present invention provides a method of preparing an oral care composition according to any relevant aspect of the present invention using a test composition that is positive in one or more assays tested using a test method according to any relevant aspect of the present invention.

[0021] MODE FOR CARRYING OUT THE INVENTION Oral biofilm is a well-known term in the art. It refers to a community of microorganisms and their products embedded in a matrix that adheres to soft tissues in the mouth, including tooth enamel and the tongue, and is an important component of the oral microbiome. The cooperative nature of the microbial community within a biofilm provides advantages to the participating bacteria, ranging from a larger habitat that enhances growth to greater resistance to host defenses and antimicrobial agents, which also enhances the pathogenicity of the microbial community.

[0022] Oral biofilms are commonly found in well-cared-for mouths, but in some situations, biofilms can lead to oral pathologies including erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis and / or dental caries.

[0023] Although mechanical disruption of biofilms by brushing or flossing can remove some of the pathogenic microorganisms and aid in oral hygiene, biofilms can rapidly regenerate. Therefore, there is a need to identify compounds and compositions that can be used alone or in combination with mechanical disruption to slow the development of oral biofilms.

[0024] The present inventors have sought to identify compounds or compositions that can be used in oral care compositions to improve oral hygiene.

[0025] The present inventors have devised a method for identifying whether a test compound or composition may have utility in an oral care composition by (a) assaying whether the test composition reduces bacterial adhesion, and / or (b) assaying whether the test composition reduces biofilm formation, and / or (c) assaying whether the test composition disrupts biofilms, and (d) assaying whether the test composition reduces the pathogenicity of Porphyromonas gingivalis, wherein a composition testing positive in one or more assays is useful in an oral health care composition.

[0026] Further information regarding the performance of the assay is specified in the accompanying examples, which are further described below.

[0027] From this study, the inventors identified several compounds or compositions that modulate bacterial adhesion and / or biofilm formation and / or disrupt biofilms: Iris species root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract.

[0028] Therefore, the present invention provides oral care compositions comprising one or more of the compounds or compositions mentioned herein that have anti-oral biofilm effects, i.e., reduce bacterial adhesion and / or reduce biofilm formation and / or disrupt biofilms.Therefore, they have utility in preventing or treating oral pathologies, including erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis and / or dental caries.

[0029] "Reduce" includes when a compound or composition has a positive result in one or more of the assays used in the embodiments of the invention described herein. By "positive result," we mean that the composition reduces biofilm abundance by more than 90% compared to a control sample, or produces a statistically significant effect in an assay (the effect being a reduction) compared to a control reaction containing the same sample mixture but lacking the test compound or composition.

[0030] "Pathogenicity" includes the amount and / or activity of gingipain produced by Porphyromonas gingivalis. Thus, by "positive result," we mean that a composition has a positive result if it reduces the amount and / or activity of gingipain compared to a control sample or produces a statistically significant effect in an assay (the effect being a reduction) compared to a control reaction containing the same sample mixture but lacking the test composition.

[0031] As used herein, " statistically significant effect " is when compound or composition has p-value of less than 0.05 (i.e., 95% confidence interval) measured by Student's T-test.As can be understood, this reduction will be beneficial to reduce the likelihood that subject will develop oral pathology, as listed above.

[0032] In some embodiments of the present invention, the oral care product is selected from the group consisting of toothpaste, tooth powder, tooth gel, tooth cleaning liquid, tooth cleaning foam, tooth tablet, mouthwash, mouth rinse, mouth spray, dental floss, chewing gum, dental aligners, lozenges, denture effervescent tablets, denture effervescent tablets and dental aligners.

[0033] As used herein, the term "oral health care composition" refers to a product that, in the normal course of use, is not intentionally swallowed for the purpose of systemic administration of a particular therapeutic agent, but is retained in the oral cavity for a time sufficient to contact substantially all dental surfaces and / or oral tissues for oral activity purposes. Oral health care compositions can be in a variety of forms, including toothpaste, tooth powder, tooth gel, tooth cleaning solution, tooth cleaning foam, tooth tablet, mouthwash, mouth rinse, mouth spray, dental floss, chewing gum, dental aligners, lozenges, denture effervescent tablets; denture effervescent tablets and dental aligners.

[0034] The oral health care compositions may also be incorporated onto floss, strips, or films for direct application or attachment to oral surfaces, or may be incorporated into devices or applicators such as toothbrushes, dental aligners, or roll-ons. Such applicators may be for single or multiple use.

[0035] As used herein, the term "dentifrice" includes paste, gel, or liquid formulations unless otherwise specified. A dentifrice composition may be a single-phase composition or a combination of two or more separate dentifrice compositions. The dentifrice composition may be in any desired form, such as deep-striped, surface-striped, multi-layered, having a gel surrounding a paste, or any combination thereof. Each dentifrice composition in a dentifrice containing two or more separate dentifrice compositions may be contained in physically separate compartments of a dispenser and dispensed side by side.

[0036] As used herein, the term "dispenser" refers to any pump, tube, or container suitable for dispensing a composition such as a dentifrice.

[0037] As noted above, the inventors have identified several compounds or compositions that can be used in oral health care compositions.

[0038] The present invention provides a solution to the above problems by providing an oral care composition comprising one or more of the following compounds or compositions: Iris species root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract.

[0039] The compounds or compositions used in the oral care compositions of the present invention are discussed below.

[0040] "Iris species root extract" is a material known in the art. It has floral notes that can be described as fatty, floral, violet, and woody. "Iris species root extract" includes extracts prepared from Iris pallida and Iris germanica, including products available from Firmenich SA under the name ORRIS CTE NAT 15 IRONE, and includes materials registered under CAS 0008002-73-1. Those skilled in the art will understand that the composition Iris florentina root extract or Iris florentina with CAS number 90045-89-9 is different from the Iris species root extract used herein.

[0041] Thus, in one embodiment, the composition Iris florentina root extract and / or Iris florentina is excluded from the root extract of Iris species used herein.

[0042] In another embodiment, the root extract of Iris species does not include Iris florentina root extract and Iris florentina. In a further embodiment, the oral care composition does not include Iris florentina root extract and / or Iris florentina.

[0043] "Cumin seed oil" is a material known in the art. It has a cumin, fatty, sweaty, peppery, green vegetable odor and a cumin, spicy, sweaty, aldehydic, green, fatty, beany, herbal, metallic flavor. "Cumin seed oil" includes CUMIN EO available from Firmenich SA, including materials registered under CAS 8014-13-9. Notably, the term "cumin seed oil" as used herein does not refer to Nigella sativa seed oil, which may be called "black cumin," obtained from Nigella sativa.

[0044] Thus, in one embodiment, cumin seed oil is obtained from the cumin seeds of Cuminum cyminum.

[0045] "Litsea cubeba oil" is a material well known in the art. It has a sweet, fresh, lemon, citral, grassy odor and a citrus, lemon, lemongrass, aldehyde, grassy flavor. "Litsea cubeba oil" includes materials registered under CAS 68855-99-2, which are available from a number of sources.

[0046] "Citrus aurantium extract" is a material known in the art. It has floral notes and can be used in perfume and fragrance applications. "Citrus aurantium extract" includes when the extract is a product named PETITGRAIN PARAGUAY EO available from Firmenich SA, and includes materials registered under CAS 0008014-17-3.

[0047] Preferably, the oral care composition of the present invention comprises one or more compounds or compositions that have positive results in two or more of the assays used in the aspects of the present invention described herein.Accordingly, a further embodiment of the present invention is one in which the oral care composition comprises Iris root extract, cumin seed oil, Litsea cubeba fruit oil and Citrus aurantium extract.

[0048] More preferably, the oral care composition of the present invention comprises one or more compounds or compositions that have positive results in three of the assays used in the aspects of the present invention described herein.Thus, a further embodiment of the present invention is one in which the oral care composition comprises one or more of the following compounds or compositions: an extract of the roots of Iris species and an extract of Citrus aurantium.

[0049] As mentioned above, the oral care compositions of the present invention comprise one or more of the compounds or compositions described herein. In some embodiments of the present invention, the oral care compositions of the present invention comprise two, three, or four of the following compounds or compositions: Iris root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract.

[0050] In one embodiment, the oral care composition of the present invention comprises an Iris root extract and cumin seed oil. In another embodiment, the oral care composition of the present invention comprises an Iris root extract and Litsea cubeba fruit oil. In yet another embodiment, the oral care composition of the present invention comprises cumin seed oil and Litsea cubeba fruit oil. In another embodiment, the oral care composition of the present invention comprises cumin seed oil and Citrus aurantium extract. In a further embodiment, the oral care composition of the present invention comprises Litsea cubeba fruit oil and Citrus aurantium extract.

[0051] In another embodiment, the oral care composition of the present invention comprises the following compounds or compositions: or a combination of cumin seed oil and Citrus aurantium and one or more of the following compounds or compositions: Iris root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract, wherein the oral care composition of the present invention comprises a combination of cumin seed oil and Citrus aurantium, excluding the aforementioned two compounds or compositions; or comprises cumin seed oil and Citrus aurantium and a combination of one or more of the following compounds or compositions: Iris root extract and Litsea cubeba fruit oil.

[0052] In a further embodiment, the oral care composition of the present invention comprises Iris species root extract and cumin seed oil, and one or more of the following compounds or compositions: Litsea cubeba fruit oil and Citrus aurantium extract.

[0053] In another embodiment, the oral care composition of the present invention comprises Iris species root extract and Litsea cubeba fruit oil, and one or more of the following compounds or compositions: cumin seed oil and bitter orange (Citrus aurantium) extract.

[0054] In another embodiment, the oral care composition of the present invention comprises an Iris species root extract and a Citrus aurantium extract, and one or more of the following compounds or compositions: Litsea cubeba fruit oil and Cumin seed oil.

[0055] In one embodiment, the oral care composition of the present invention comprises cumin seed oil and Litsea cubeba fruit oil, and one or more of the following compounds or compositions: Iris species root extract and Citrus aurantium extract.

[0056] In another embodiment, the oral care composition of the present invention comprises cumin seed oil and bitter orange (Citrus aurantium), and one or more of the following compounds or compositions: Iris species root extract and Litsea cubeba fruit oil.

[0057] In yet another embodiment, the oral care composition of the present invention comprises Litsea cubeba fruit oil and Citrus aurantium, and one or more of the following compounds or compositions: Iris species root extract and Cumin seed oil.

[0058] In a specific embodiment, the root extract of Iris species is a material registered under CAS 0008002-73-1.

[0059] In a specific embodiment, the cumin seed oil is a material registered under CAS 8014-13-9.

[0060] In a specific embodiment, Litsea cubeba fruit oil is a material registered under CAS 68855-99-2.

[0061] In a specific embodiment, the bitter orange (Citrus aurantium) extract is a material registered under CAS 0008014-17-3.

[0062] In certain embodiments, an oral care composition comprising Iris species root extract, a material registered under CAS 0008002-73-1, and / or Cuminum cyminum seed oil, a material registered under CAS 8014-13-9, and / or Litsea cubeba fruit oil, a material registered under CAS 68855-99-2, and / or Citrus aurantium extract, a material registered under CAS 0008014-17-3.

[0063] As can be appreciated, the amount of the compound or composition can vary according to the particular compound or composition and formulation and intended use.

[0064] However, one embodiment of the present invention provides an oral care composition according to the invention, in which the compound or composition is in a concentration of 0.001 to 5%, particularly preferably 0.005 to 3%, preferably 0.5 to 2%, in each case relative to the total weight of the oral care composition according to the invention.

[0065] Certain embodiments of the present invention provide oral care compositions of the present invention further comprising one or more of the following ingredients: a flavor system, a coolant, a surfactant, a humectant, a pigment, an antimicrobial agent, a thickener, a fluoride source, an anti-tartar agent, and / or a preservative.

[0066] In some embodiments, the composition further comprises a flavor system. The flavor system can mask unpleasant tastes and sensations caused by certain components of the composition, such as antimicrobial actives or peroxides. Without intending to be limited to any particular theory, a pleasant-tasting composition improves user compliance with the prescribed or recommended use of oral care products. The flavor system can also include conventional flavor ingredients, particularly flavor ingredients that are relatively stable in the presence of common oral care product carrier materials or excipients. The combination of the selected flavor system with the composition presented herein can provide a high-impact cooling sensation with a balanced flavor profile.

[0067] In some embodiments, the fragrance system comprises oil of wintergreen, cassia, sage, parsley oil, marjoram, orange, cis-jasmone, 2,5-dimethyl-4-hydroxy-3(2H)-furanone, 5-ethyl-3-hydroxy-4-methyl-2(5H)-furanone, vanillin, ethyl vanillin, anisaldehyde, 3,4-methylenedioxybenzaldehyde, 3,4-dimethoxybenzaldehyde, 4-hydroxybenzaldehyde, 2-methoxybenzaldehyde, benzaldehyde; propenylguaethol, heliotropin, 4-cis-heptenal, diacetyl, methyl-p-tert-butylphenyl ether ... The composition may contain additional fragrance ingredients including, but not limited to, methyl acetate, methyl salicylate, ethyl salicylate, l-menthyl acetate, oxanone, alpha-irisone, ethyl butyrate, ethyl acetate, methyl anthranilate, isoamyl acetate, isoamyl butyrate, allyl caproate, eugenol, eucalyptol, octanol, octanal, decanol, decanal, phenylethyl alcohol, benzyl alcohol, alpha-terpineol, maltol, ethyl maltol, anethole, dihydroanethole, carvone, menthone, beta-damascenone, and mixtures thereof.

[0068] Generally, suitable fragrance ingredients are those containing structural features and functional groups that are resistant to redox reactions. These include derivatives of fragrance chemicals that are saturated or contain stable aromatic rings or ester groups. Also suitable are fragrance chemicals that can undergo some oxidation or decomposition without significantly changing the fragrance character or profile. The fragrance ingredients can be provided in the composition as pure or purified chemicals, or by the addition of natural oils or extracts that have preferably undergone a refining process to remove relatively unstable components that may decompose and alter the desired fragrance profile, resulting in a product that is less acceptable from an organoleptic standpoint. Flavorings can generally be used in the composition at levels of about 0.001% to about 5% by weight of the composition.

[0069] In some embodiments, the flavor system may further include a sweetener. Suitable sweeteners include those known in the art, including both natural and artificial sweeteners. Some suitable water-soluble sweeteners include monosaccharides, disaccharides, and polysaccharides, such as xylose, xylitol, ribose, glucose (dextrose), mannose, galactose, fructose (levulose), sucrose (sugar), maltose, invert sugar (a mixture of fructose and glucose derived from sucrose), partially hydrolyzed starch, corn syrup solids, dihydrochalcones, monellin, stevioside, and glycyrrhizin. Sweeteners derived from Monk Fruit, including mogrosides, are also included. Sweeteners derived from Stevia rebaudiana, including stevioside and rebaudiosides (especially rebaudioside A), are also included. Suitable water-soluble artificial sweeteners include soluble saccharin salts, i.e., sodium or calcium saccharin, cyclamate salts, sodium, ammonium, or calcium salts of 3,4-dihydro-6-methyl-1,2,3-oxathiazin-4-one-2,2-dioxide, potassium salt of 3,4-dihydro-6-methyl-1,2,3-oxathiazin-4-one-2,2-dioxide (acesulfame-K), the free acid form of saccharin, and the like. Other suitable sweeteners include dipeptide-based sweeteners, such as L-aspartic acid-derived sweeteners, such as L-aspartyl-L-phenylalanine methyl ester (aspartame) and the materials described in U.S. Pat. No. 3,492,131, L-α-aspartyl-N-(2,2,4,4-tetramethyl-3-thietanyl)-D-alaninamide hydrate, the methyl esters of L-aspartyl-L-phenylglycerin and L-aspartyl-L-2,5,dihydrophenyl-glycine, L-aspartyl-2,5-dihydro-L-phenylalanine, L-aspartyl-L-(1-cyclohexylene)-alanine, and the like.Water-soluble sweeteners derived from natural water-soluble sweeteners, such as the chlorinated derivatives of ordinary sugar (sucrose), known by the product description of sucralose, as well as protein-based sweeteners, such as those from Thaumatoccous daniellii (thaumatins I and II), can be used.

[0070] In some embodiments, the composition may contain from about 0.1% to about 10%, or alternatively from about 0.1% to about 1%, of sweetener, by weight of the composition.

[0071] In some embodiments, the flavor system may further include salivating agents, warming agents, and numbing agents, which may be present in the composition at levels of from about 0.001% to about 10%, or alternatively from about 0.1% to about 1%, by weight of the composition.

[0072] Suitable salivating agents include Jambu® manufactured by Takasago International Corporation. Suitable numbing agents include benzocaine, lidocaine, clove bud oil, and ethanol. Examples of warming agents include ethanol, chili pepper, and nicotinic acid esters, such as benzyl nicotinate.

[0073] In some embodiments, the oral care compositions of the present invention may further comprise a cooling agent, such as those set forth in U.S. Patent Nos. 9,394,287 and 9,732,071. Additional examples of cooling agents include 5-methyl-2-(propan-2-yl)cyclohexyl-N-ethyloxamate, N-ethyl-p-menthanecarboxamide (WS-3, also known as menthane-3-carboxylic acid-N-ethylamide), N-2,3-trimethyl-2-isopropylbutanamide (WS-23), menthyl lactate (Frescolat® ML), menthone glycerin acetal (Frescolat® MGA), monomenthyl succinate (Physcool®), monomenthyl glutarate, and the like. Nomenthyl, O-menthyl-glycerin, menthyl-N,N-dimethylsuccinamate, N-(4-cyanomethylphenyl)-p-menthanecarboxamide, N-(2-(pyridin-2-yl)ethyl)-3-p-menthanecarboxamide, menthol and menthol derivatives (e.g., L-menthol, D-menthol, racemic menthol, isomenthol, neoisomenthol, neomenthol), menthyl ethers (e.g., (I-menthoxy)-1,2-propanediol, (I-menthoxy)-2-methyl-1,2-propanediol, 1-menthyl-methyl ether), menthyl esters (e.g., menthyl formate, menthyl acetate, menthyl isobutyrate, menthyl lactate, L-menthyl L-lactate, L-menthyl D-lactate, menthyl (2-methoxy)acetate, menthyl (2-methoxyethoxy)acetate, menthyl pyroglutamate), N-(4-cyanomethylphenyl)-p-menthanecarboxamide, N-(2-(pyridin-2-yl)ethyl)-3-p-menthanecarboxamide, menthyl carbonate (e.g., menthyl propylene glycol carbonate), carbonate, menthyl ethylene glycol carbonate, menthyl glycerin carbonate or mixtures thereof), menthanecarboxylic acid amides (e.g., menthanecarboxylic acid-N-ethylamide [WS3], N-α-(menthane-carbonyl)glycine ethyl ester [WS5], menthanecarboxylic acid-N-(4-cyanophenyl)amide, menthanecarboxylic acid-N-(alkoxyalkyl)amides), menthone and menthone derivatives (e.g., L-menthone glycerin ketal), 2,3-dimethyl-2-(2-propyl)butyric acid derivatives derivatives (e.g., 2,3-dimethyl-2-(2-propyl)butyric acid-N-methylamide [WS23]), isopulegol or its esters (1-(-)-isopulegol, 1-(-)-isopulegol acetate), menthane derivatives (e.g., p-menthane-3,8-diol), N-(4-cyanomethylphenyl)-p-menthanecarboxamide, N-(2-(pyridin-2-yl)ethyl)-3-p-menthanecarboxamide, cubebol, or synthetic or natural mixtures containing cubebol, pyrrolidone derivatives of cycloalkyldione derivatives, lydone derivatives (e.g., 3-methyl-2(1-pyrrolidinyl)-2-cyclopenten-1-one) or tetrahydropyrimidin-2-ones (e.g., icilin or related compounds such as those described in WO 2004 / 026840), N-(4-cyanomethylphenyl)-p-menthanecarboxamide, N-(2-(pyridin-2-yl)ethyl)-3-p-menthanecarboxamide, menthyl ethers (e.g., (I-menthoxy)-1,2-propanediol, (I-menthoxy)-2-methyl-1,2-propanediol), more polar menthyl esters (e.g., menthyl lactate, L-menthyl L-lactate, L-menthyl D-lactate, menthyl-(2-methoxy)acetate, menthyl-(2-methoxyethoxy)acetate, menthyl pyroglutamate), menthyl carbonate (e.g., menthyl propylene glycol carbonate, menthyl ethylene glycol carbonate, menthyl glycerin carbonate), half esters of menthol with dicarboxylic acids or their derivatives (e.g., monomenthyl succinate, monomenthyl glutarate, monomenthyl malonate, O-menthyl succinate-N,N-(dimethyl) amide, O-menthyl succinic acid ester amide), 3,4-methylenedioxycinnamic acid-N-cyclohexyl-N-2-pyridylamide, isopropyl-(5-methoxy-2-pyridin-2-yl-pyrimidin-4-yl)-amine, 3,4,6,7,11b,12-hexahydro-3,3-dimethyl-spiro[13H-dibenzo[a,f]quinolizine-1-3,2'-[1,3]dithiolane]-1(2H)-one, 5,6,10b,11-tetrahydro-3-methyl-spiro[12H-benzo[a]furo[3,4-f]quinolizine-1-2,2'-[1,3]dithiolane]-1(3H)-one. The most preferred cooling compounds are 5-methyl-2-(propan-2-yl)cyclohexyl-N-ethyloxamate, N-ethyl-p-menthanecarboxamide (WS-3, also called menthane-3-carboxylic acid-N-ethylamide), menthyl lactate (Frescolat® ML), menthone glycerin acetal (Frescolat® MGA), N-(4-cyanomethylphenyl)-p-menthanecarboxamide, and (I-menthoxy)-1,The compound is selected from the group consisting of 2-propanediol, 2-(4-methylphenoxy)-N-(1H-pyrazol-5-yl)-N-(2-thienylmethyl)acetamide, 2-(4-methylphenoxy)-N-(1H-pyrazol-3-yl)-N-(2-thienylmethyl)acetamide, and a mixture of 2-(4-methylphenoxy)-N-(1H-pyrazol-5-yl)-N-(2-thienylmethyl)acetamide and 2-(4-methylphenoxy)-N-(1H-pyrazol-3-yl)-N-(2-thienylmethyl)acetamide.

[0074] In addition to the above ingredients, the composition may include additional optional ingredients and / or orally acceptable carrier materials.

[0075] In some embodiments, the oral care composition comprises a surfactant component.

[0076] Any orally acceptable surfactant can be used, most of which are anionic, nonionic or amphoteric.Suitable anionic surfactants include, but are not limited to, sodium lauryl sulfate, sodium coconut monoglyceride sulfonate, sodium lauryl sarcosinate, sodium lauryl isethionate, sodium laureth carboxylate and sodium dodecylbenzenesulfonate.Suitable nonionic surfactants include poloxamer, polyoxyethylene sorbitan ester, fatty alcohol ethoxylate, alkylphenol ethoxylate, tertiary amine oxide, tertiary phosphine oxide, dialkyl sulfoxide, etc.Suitable amphoteric surfactants include C 100 having anionic groups such as carboxylate, sulfate, sulfonate, phosphate or phosphonate. 8~20 Derivatives of aliphatic secondary and tertiary amines are included.

[0077] In some embodiments, the surfactant component comprises (i) a surfactant selected from the group consisting of poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) block copolymers, poly(oxyethylene)-modified hydrogenated castor oil, and poly(oxyethylene)-modified fatty acid monoesters of sorbitan, and (ii) a surfactant selected from the group consisting of polyol esters and sugar esters.

[0078] In some embodiments, the oral care composition comprises a pigment. Any suitable orally acceptable pigment can be used, including talc, mica, magnesium carbonate, calcium carbonate, magnesium silicate, magnesium aluminum silicate, silica, titanium dioxide, zinc oxide, red iron oxide, yellow iron oxide, brown iron oxide, and black iron oxide, ferric ammonium ferrocyanide, manganese violet, ultramarine, titanium dioxide coated mica, bismuth oxychloride.

[0079] In some embodiments, the oral care composition comprises a fluoride ion source. Suitable fluoride ion sources include stannous fluoride, sodium fluoride, potassium fluoride, potassium monofluorophosphate, sodium monofluorophosphate, ammonium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and combinations thereof.

[0080] In some embodiments, the oral care composition comprises an antibacterial agent. Suitable antibacterial agents include ethanol, triclosan, cetylpyridinium chloride (CPC), chlorhexidine (CHX), isopropylmethylphenol (IPMP), zinc sulfate (ZnSO), zinc citrate, and zinc chloride (ZnCl).

[0081] Some embodiments of the present invention provide oral care compositions of the present invention that are coated or encapsulated.

[0082] Various methods are known in the art for preparing oral care compositions in which one or more ingredients are coated or encapsulated in powder-coated dissolvable film fragments, e.g., the film matrix contains a water-insoluble active agent.

[0083] A further aspect of the present invention provides an oral care or consumer product, preferably a food or beverage product, particularly preferably a nutritional or recreational product, comprising the oral care composition of the present invention. In a related embodiment, the present invention provides an oral care product comprising the oral care composition of the present invention.

[0084] In some embodiments, the oral care composition includes a humectant component. Examples of humectants include propylene glycol, hexylene glycol, and butylene glycol, aloe vera gel, alpha hydroxy acids such as lactic acid, egg yolk and egg white, glyceryl triacetate, honey, lithium chloride, molasses, polymer polyols such as polydextrose, quillaja, sodium hexametaphosphate E452i, sugar alcohols (sugar polyols) such as glycerol, sorbitol, xylitol, maltitol, urea, and castor oil.

[0085] A further aspect of the present invention provides one or more of the following compounds or compositions for use as an anti-oral biofilm agent: lemongrass oil, lime oil, peppermint oil (e.g., mint piperita reco nat, mint piperita boulder sx, or mint piperita yakima single cut), gamma octalactone, 3-hexenyl acetate, butanol, geraniol, lavender oil, beta ionone, isoamyl alcohol, cinnamaldehyde, clove oil, peppermint oil (e.g., mint arvensis tpc), linseed oil, methyl (2-pentyl-3-oxocyclopentyl) acetate, and thymol, or the oral care composition of any of the preceding aspects of the invention.

[0086] A further aspect of the present invention provides consumer products comprising the oral care compositions of the present invention.

[0087] In one embodiment, the consumer product is a food or beverage product, hi another embodiment, the consumer product is a nutritional or recreational product.

[0088] A preferred embodiment of a consumer product, wherein the oral care composition of the present invention comprises isoamyl alcohol, linseed oil, and methyl(2-pentyl-3-oxocyclopentyl). Preferably, the oral care composition of the present invention comprises 10% isoamyl alcohol, 10% linseed oil, and 2.5% methyl(2-pentyl-3-oxocyclopentyl).

[0089] A preferred embodiment of a consumer product, wherein the oral care composition of the present invention comprises mint arvensis tpc and mint piperita yakima single cut. Preferably, the oral care composition of the present invention comprises 16.67% mint arvensis tpc and 16.67% mint piperita yakima single cut.

[0090] A preferred embodiment of the consumer product wherein the oral care composition of the present invention comprises cinnamaldehyde and clove oil. Preferably, the oral care composition of the present invention comprises 15% cinnamaldehyde and 15% clove oil.

[0091] "Consumer products" include, by way of example, confectioneries such as chewing gum, lozenges, and hard candies; beverages such as soft drinks and flavored waters; dairy drinks and products such as dairy formulas, yogurt drinks, lactose-free yogurt, acidified milk, coffee cream or whipped cream, cheese, quark, ice cream, and other frozen desserts. Alcoholic and non-alcoholic beverages are also included. Other suitable food and beverage products will be known to those skilled in the art. Consumer products do not include preparations having a dosage form that prevents the compounds or compositions of the oral care composition from contacting a person's oral cavity, i.e., that prevents the compounds or compositions from fully reaching their (therapeutic) target destination, such as tablets in which the active ingredient is encapsulated and the encapsulation does not disintegrate in the mouth.

[0092] A further aspect of the present invention provides a method of treating or preventing erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis and / or dental caries, the method comprising the step of applying a composition according to any preceding aspect of the invention to the oral cavity of a person in need thereof.

[0093] In one embodiment, the invention provides a non-therapeutic method of caring for a person's oral cavity, the method comprising applying to the person's oral cavity a composition according to any preceding aspect of the invention.

[0094] A further aspect of the present invention provides an oral care composition comprising one or more of the following compounds or compositions: Iris species root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract, for use in treating an oral condition. In a related embodiment, the present invention provides an oral care composition according to any preceding aspect of the invention, for use in treating an oral condition.

[0095] In one embodiment, the oral condition is associated with an oral biofilm in the oral cavity of a person.

[0096] In a further embodiment, the oral condition is related to the amount and / or activity of gingipains in a person's oral cavity.

[0097] In another embodiment, the oral condition is selected from the group consisting of erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis, dental caries, or a combination thereof.

[0098] In yet another embodiment, the oral care composition is administered in an amount sufficient to reduce bacterial adhesion, and / or reduce biofilm formation, and / or disrupt biofilms, and / or reduce the virulence of Porphyromonas gingivalis in the oral cavity of a human.

[0099] In related embodiments, the amount of the compound or composition sufficient to reduce bacterial adhesion and / or biofilm formation and / or disrupt biofilms and / or reduce the pathogenicity of Porphyromonas gingivalis in the human oral cavity is 0.001 to 5%, particularly preferably 0.005 to 3%, preferably 0.05 to 2.5%, preferably 0.1 to 2.5%, and preferably 0.5 to 2%, in each case based on the total weight of the composition. The amount of the compound or composition sufficient to reduce bacterial adhesion and / or biofilm formation and / or disrupt biofilms and / or reduce the pathogenicity of Porphyromonas gingivalis can be determined by the methods for identifying test compositions having use in oral health care described herein below.

[0100] In further embodiments, the oral care composition is administered in an amount sufficient to reduce the amount and / or activity of gingipain in a person's oral cavity. In certain embodiments, the amount and / or activity of gingipain is reduced compared to a control sample or produces a statistically significant effect in an assay (the effect being a reduction) compared to a control reaction containing the same sample mixture but lacking the test composition.

[0101] In related embodiments, the amount of compound or composition sufficient to reduce the amount and / or activity of gingipain in the human oral cavity is 0.001-5%, particularly preferably 0.005-3%, preferably 0.05-2.5%, preferably 0.1-2.5%, and preferably 0.5-2%, in each case based on the total weight of the composition. The amount of compound or composition sufficient to reduce bacterial adhesion and / or reduce biofilm formation and / or disrupt biofilms and / or reduce the pathogenicity of Porphyromonas gingivalis can be determined by the methods for identifying test compositions with uses in oral health care described herein below.

[0102] In another embodiment, the oral care composition is administered in an amount sufficient to reduce bacterial adhesion, and / or reduce biofilm formation, and / or disrupt biofilms, and / or reduce the virulence of Porphyromonas gingivalis, and reduce the amount and / or activity of gingipains in the oral cavity of a human.

[0103] A further aspect of the present invention provides the use of an oral care composition according to any aspect of the present invention for treating or preventing erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis and / or dental caries.

[0104] "Anti-oral biofilm agents" include compounds or compositions that prevent or treat oral conditions associated with oral biofilms. Thus, the present invention includes compounds and compositions designated herein for use in the prevention or treatment of aggressive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis, and / or dental caries.

[0105] A further aspect of the present invention is a method for identifying a test composition having use in oral health care, comprising the steps of: (a) assaying whether the test composition reduces bacterial adhesion; and / or (b) assaying whether the test composition reduces biofilm formation; and / or (c) assaying whether the test composition disrupts the biofilm; and / or (d) assaying whether the test composition reduces the pathogenicity of Porphyromonas gingivalis. Including, Methods are provided in which compositions that test positive in one or more assays are useful in oral health care compositions.

[0106] The method of the present invention determines whether a test composition has a use in oral health care according to a positive result in one or more of the assays used in the embodiments of the present invention. By "positive result", we mean that the composition produces a statistically significant effect in the assay compared to a control reaction containing the same sample mixture but not the test composition.

[0107] The accompanying examples provide methodological details for each assay of this method of the invention. Further information is also provided below.

[0108] One assay is used to determine whether a test composition reduces bacterial adhesion. When performing this assay, a dental enamel replacement material is used as a substrate suitable for the adhesion of oral biofilm-producing bacteria. The dental enamel replacement material is exposed to oral biofilm-producing bacteria in the presence and absence of the test composition, and after an appropriate incubation time, the effect of the test composition on bacterial adhesion is determined. Therefore, reducing oral biofilm-producing bacterial adhesion to dental enamel replacement material is beneficial because it reduces the formation of dental biofilms and therefore reduces the pathologies associated with oral biofilms (as described above).

[0109] Therefore, this assay is designed to mimic the adhesion of early colonizing species of bacteria to a sterile surface, specifically to dental enamel replacement materials. The assay is performed with and without treatment with the test composition. This is step (a) of the assay recited in the method of the present invention.

[0110] Thus, one embodiment of the method for identifying a test composition is one in which the assay in step (a) comprises exposing a substrate to saliva and / or bacteria in the presence or absence of the test composition and determining whether the test composition reduces bacterial adhesion to the substrate.

[0111] Suitable dental enamel replacement materials include hydroxyapatite (HA) discs or bovine dentin and enamel.The dental enamel replacement materials are exposed to oral biofilm-producing microorganisms in the presence and absence of test compositions for a certain period of time, for example, 30 minutes to 24 hours, preferably 24 hours.After this, the biofilm is collected and analyzed by recording the number and condition of microorganisms.

[0112] Further assays are used to determine whether test compositions reduce biofilm formation. This assay mimics the development of dental biofilms at an early stage. When performing this assay, assay plates with saliva-coated wells are exposed to test compositions multiple times during an incubation period, and then the number and condition of microorganisms are recorded to analyze the effect of the test compositions on biofilm formation.

[0113] The assay plates are exposed to the test composition multiple times, preferably twice, within a 24 hour period.

[0114] Therefore, this assay is designed to mimic the early stage of biofilm formation.This assay is carried out with and without treatment with test composition, and treatment is applied when biofilm develops on dental enamel replacement material as described above.This is the step (b) of the assay listed in the method of the present invention.

[0115] Thus, an embodiment of the method of the present invention is one in which the assay in step (b) comprises exposing the substrate to saliva and / or bacteria under incubation conditions for at least 24 hours, then exposing the incubation mixture to a test composition, and determining whether the test composition reduces biofilm formation on the substrate.

[0116] An additional assay is used to determine whether the test composition disrupts biofilms. This assay is designed to evaluate the ability of the test composition to disrupt mature biofilms. Biofilms are prepared according to the formation assay described above. Then, once the biofilms have matured (approximately 3-7 days after the start of incubation), they are exposed to the test composition multiple times over the test period, and the effect of the test composition on biofilm formation is then analyzed by recording the number and condition of the microorganisms.

[0117] Therefore, this assay is designed to mimic mature biofilm.This assay is carried out with and without treatment with test composition, and treatment is applied for at least 3 days, preferably about 7 days, after biofilm develops on dental enamel replacement material as described above.This is the step (c) of the assay listed in the method of the present invention.

[0118] In one embodiment of the method for identifying a test composition, the assay in step (c) comprises exposing the substrate to saliva and / or bacteria under incubation conditions for at least 72 hours to allow a biofilm to form on the substrate, then exposing the incubation mixture to the test composition and determining whether the test composition disrupts the biofilm.

[0119] A further embodiment of the method for identifying a test composition is one in which the effect of the test composition on a biofilm is determined by harvesting the biofilm and determining the amount and type of bacteria present in the biofilm.

[0120] A further embodiment of the method for identifying a test composition comprises preparing an oral care composition using a test composition that is positive in one or more assays.

[0121] A further aspect of the present invention provides a method of preparing an oral care composition according to any relevant preceding aspect of the present invention using a test composition that tests positive in one or more assays tested in a test method according to any relevant preceding aspect of the present invention.

[0122] In one embodiment, the present invention provides a method suitable for producing an oral care composition according to any preceding aspect of the invention, comprising: (a) assaying whether the test composition reduces bacterial adhesion; and / or (b) assaying whether the test composition reduces biofilm formation; and / or (c) assaying whether the test composition disrupts the biofilm; and / or (d) Assaying whether the test composition reduces the pathogenicity of Porphyromonas gingivalis. The present invention provides a method for identifying a test composition having use in oral health care, the method comprising:

[0123] In another embodiment, the present invention provides a method suitable for producing an oral care composition according to any preceding aspect of the invention, comprising: 1) providing a compound to be tested, preferably Iris species root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract; 2) (a) assaying whether the test composition reduces bacterial adhesion; and / or (b) assaying whether the test composition reduces biofilm formation; and / or (c) assaying whether the test composition disrupts the biofilm; and / or (d) Assaying whether the test composition reduces the pathogenicity of Porphyromonas gingivalis. identifying a test compound or composition that has use in oral health care, comprising: 3) combining the compound or composition identified in step 2 with an oral care product carrier material or excipient; 4) optionally further adding one or more of the following ingredients: a flavor system, a cooling agent, a surfactant, a humectant, a pigment, an antimicrobial agent, a thickener, a fluoride source, an anti-tartar agent, and / or a preservative; The present invention provides a method comprising:

[0124] In a further embodiment, the compound or composition identified in step 2 is admixed with an oral care product carrier material or excipient in that the compound or composition is in each case at a concentration of 0.001 to 5%, particularly preferably 0.005 to 3%, preferably 0.05 to 2.5%, preferably 0.1 to 2.5%, preferably 0.5 to 2% relative to the total weight of the composition.

[0125] The present invention will now be described in further detail by the following examples which illustrate the benefits and advantages of the present invention.

[0126] Example Example 1. In vitro screening of fragrance ingredients for anti-biofilm activity Inoculum preparation A total of 12 bacterial strains were selected based on scientific literature. These strains were grown in the medium recommended by the strain supplier. Broth cultures were adjusted to log7 CFU / mL using growth medium containing 20% ​​glycerol. For Corynebacterium matruchotii (C. matruchotii), colony culture plates were washed with growth medium containing glycerol, and the cell suspension was then homogenized by vortexing with glass beads. Aerobic and anaerobic strains were mixed and aliquoted separately. The inoculum was stored at -80°C until use.

[0127] [Table 1]

[0128] Preparation of saliva and oral inocula. Saliva and oral microbiota samples were collected from healthy volunteers by passive salivation using a previously described method [1].

[0129] (a) Bacterial adhesion assay Pegs on a 96-well MBEC plate (Innovotech, Canada) were immersed in saliva for pellicle formation. Overnight cultures of Actinomyces oris (A. oris), Actinomyces naeslundii (A. naeslundii), Streptococcus mitis (S. mitis), and Streptococcus oralis (S. oralis) were normalized to an OD of 0.1 using 0.85% NaCl and mixed in equal proportions. The plate was treated with the sample for 2 minutes and then incubated with the culture mixture for 30 minutes at 37°C and 5% CO2. The pegs on the 96-well plate were then washed three times before collection.

[0130] (b) Biofilm formation assay Saliva-coated 96-well MBEC plates were anaerobically incubated with the inoculum overnight. The next day, the inoculum was replaced with modified BHI broth (BHI supplemented with 1 g / L mucin, 0.5 mg / L vitamin K, and 10 mg / L hemin). The devices were treated twice for 2 minutes to mimic the application of dental care products, after which the treatment solution was replaced with fresh modified BHI broth, and the device incubation continued. Biofilms were harvested after 2 days.

[0131] (c) Biofilm disruption assay Inoculation and incubation were performed in the same manner as described for the formation assay, except that the incubation time was extended to 7 days, and then mature biofilms were subjected to twice-daily treatments similar to the formation assay for 3 days before harvesting.

[0132] Biofilm collection To harvest adherent cells, the pegs of the MBEC device were immersed in 200 μL of saline per well. The plates were sonicated in an ultrasonic bath to obtain a cell suspension. For adhesion assays, the suspension was serially diluted and plated on tryptic soy agar using a Microlab STAR (Hamilton). For formation and disruption assays, the suspension was used for SYTO9 staining using the LIVE / DEAD® BacLight Bacterial Viability Kit L7012 (Thermo Fisher Scientific) according to the manufacturer's instructions. The relative amount of fluorescence was calculated by assigning the control sample to 100%. Differences between treatments and controls were compared using Student's t-test.

[0133] result Table 2 lists all compounds and compositions that resulted in biofilm reduction in any of the three assays. A component is "positive" if it reduces biofilm abundance by more than 90% compared to control samples (Δ>90) or produces a statistically significant effect (p-value<0.05).

[0134] [Table 2]

[0135] Example 2. In vitro study of the effects of fragrance ingredients on the pathogenicity of Porphyromonas gingivalis The following protocol was used to determine the effect of a compound or composition on the pathogenicity of Porphyromonas gingivalis.

[0136] Gingipain activity was measured according to the method of a previous study (1) with slight modifications. Overnight P. gingivalis cultures were harvested by centrifugation, washed, and suspended in PBS to reach an optical density of 2 for Kgp activity and 0.02 for Rgp activity.

[0137] P. gingivalis cells were mixed with the specific substrates of Kgp (1 mM, L-lysine-p-nitroanilide dihydrobromide) or Rgp (1 mM, N-α-benzoyl-dl-arginine-p-nitroanilide hydrochloride) and sample solution in a 5:4:1 ratio. The mixture was incubated in a spectrophotometer at 37°C. The absorbance at 405 nm was recorded for 20 hours. The reading at 10 hours was used to calculate relative activity, and the absorbance of the sample was converted to a percentage of the control (designated 100).

[0138] The data is shown in Table 3 below.

[0139] [Table 3]

[0140] Example 3. Composition of the perfume ingredient mixture Nine mixtures were made using the ingredients in Table 3. The compositions are shown in Table 4.

[0141] [Table 4]

[0142] Example 4. In vitro study of the effect of a fragrance ingredient mixture on the pathogenicity of Porphyromonas gingivalis The experiment was carried out using the same procedure as described in Example 2. The data are shown in Table 5.

[0143] [Table 5]

Claims

1. 1. An oral care composition comprising one or more of the following compounds or compositions: Iris species root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract.

2. 2. The oral care composition according to claim 1, wherein the compound or composition is present in a concentration of 0.001 to 5%, particularly preferably 0.005 to 3%, preferably 0.05 to 2.5%, preferably 0.1 to 2.5%, preferably 0.5 to 2%, in each case relative to the total weight of the oral care composition.

3. 3. The oral care composition of claim 1 or 2, further comprising one or more of the following ingredients: a flavor system, a cooling agent, a surfactant, a humectant, a pigment, an antimicrobial agent, a thickener, a fluoride source, an anti-tartar agent, and / or a preservative.

4. 4. The oral care composition of claim 1, which is coated or encapsulated.

5. An oral care or consumer product, preferably a food or beverage consumer product, more preferably a nutritional or recreational product, comprising the oral care composition of any one of claims 1 to 4.

6. 6. The oral care product of claim 5, selected from the group consisting of toothpaste, tooth powder, tooth gel, tooth cleaning liquid, tooth cleaning foam, tooth tablet, mouthwash, mouth rinse, mouth spray, dental floss, chewing gum, dental aligner, lozenge, denture effervescent tablet; denture effervescent tablet and dental aligner.

7. 10. A method for treating or preventing erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis and / or dental caries, comprising the step of applying a composition according to any one of claims 1 to 6 to the oral cavity of a person in need thereof.

8. 1. An oral care composition comprising one or more of the following compounds or compositions: Iris species root extract, cumin seed oil, Litsea cubeba fruit oil, and Citrus aurantium extract, for use in treating an oral condition.

9. 9. The oral care composition for use according to claim 8, wherein the oral condition is selected from the group consisting of erosive tooth demineralization, gingivitis, dental plaque, periodontitis, halitosis, dental caries or a combination thereof.

10. 1. A method for identifying a test composition having use in oral health care, comprising: (a) assaying whether the test composition reduces bacterial adhesion; and / or (b) assaying whether the test composition reduces biofilm formation; and / or (c) assaying whether the test composition disrupts the biofilm; and / or (d) assaying whether the test composition reduces the pathogenicity of Porphyromonas gingivalis. Including, The method, wherein compositions testing positive in one or more assays are useful in oral health care compositions.

11. 11. The method of claim 10, wherein the assay in step (a) comprises exposing a substrate to saliva and / or bacteria in the presence or absence of a test composition and determining whether the test composition reduces bacterial adhesion to the substrate.

12. 11. The method of claim 10, wherein the assay in step (b) comprises exposing a substrate to saliva and / or bacteria under incubation conditions for at least 24 hours, then exposing the incubation mixture to a test composition, and determining whether the test composition reduces biofilm formation on the substrate.

13. 11. The method of claim 10, wherein the assay in step (c) comprises exposing a substrate to saliva and / or bacteria under incubation conditions for at least 72 hours to allow a biofilm to form on the substrate, then exposing the incubation mixture to a test composition and determining whether the test composition disrupts the biofilm.

14. 14. The method of any one of claims 10 to 13, wherein the effect of the test composition on the biofilm is determined by harvesting the biofilm and determining the amount and type of bacteria present in the biofilm.

15. 15. The method of any one of claims 10 to 14, comprising preparing an oral care composition using a composition that tests positive in one or more assays.

16. 16. A method of preparing an oral care composition according to any one of claims 1 to 9 using a composition that tests positive in one or more assays tested by the method of any one of claims 10 to 15.

Images